Adiponectin as a Protective Factor Against the Progression

Toward Type 2 Diabetes Mellitus in

Postmenopausal Women by Assadi, Majid et al.
icine®
ONAL STUDYMed
OBSERVATIAdiponectin as a Protective Factor Against the Progression
Toward Type 2 Diabetes Mellitus in
Postmenopausal Women, Mohammad Reza K i, MD,
yaHossein Darabi, MS, Alireza Raeisi, MD
Afshin Ostovar, PhD, Majid Assadi, MD, Kam, a
of type 2 diabetes mellitus after the menopause.
(Medicine 94(33):e1347)
knowledge, the presen
ing adiponectin as a
nopausal women.
Editor: Yongjie Ma.
Received: May 16, 2015; revised: July 8, 2015; accepted: July 15, 2015.
From the Department of Endocrine Disorders, The Persian Gulf Tropical
Medicine Research Center, Bushehr University of Medical Sciences,
Bushehr, Iran (HD, MRK, IN); Department of Infectious Diseases, The
Persian Gulf Tropical Medicine Research Center, Bushehr University of
Medical Sciences, Bushehr, Iran (AR, AO, KV); The Persian Gulf Nuclear
Medicine Research Center, Bushehr University of Medical Sciences,
Bushehr, Iran (MA); Department of Endocrinology and Metabolism, NYU
Langone Medical Center, NYU, New York, USA (KA); Department on
Internal Medicine, NYU Langone Medical Center, NYU, New York, USA
(KA); and Department of Biochemistry, The Persian Gulf Marine
Biotechnology Research Center, Bushehr University of Medical Sciences,
Bushehr, Iran (SD)
Correspondence: Iraj Nabipour, The Persian Gulf Tropical Medicine
Research Center, Boostan 19 Alley, Imam Khomeini Street,
7514763448 Bushehr, Iran (e-mail: inabipour@gmail.com).
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution-NoDerivatives License 4.0, which allows for redistribution,
commercial and non-commercial, as long as it is passed along unchanged
and in whole, with credit to the author.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000001347
Medicine  Volume 94, Number 33, August 2015alantarhormoz
, Katayoun VaSina Dobaradaran, PhD
Abstract: Serum adiponectin levels have been suggested to be pre-
dictors of type 2 diabetes mellitus in diverse populations. However, the
relationship between circulating adiponectin levels and the risk of
development of type 2 diabetes in postmenopausal women has not
been investigated.
A total of 382 healthy postmenopausal women who participated in a
prospective cohort study were followed for 5.8 years. Type 2 diabetes
mellitus was defined according to the criteria set out by the American
Diabetes Association. Adiponectin, osteoprotegerin (OPG), and high-
sensitivity C-reactive protein (hs-CRP) levels were measured using
ELISA.
Of 195 women who did not have diabetes at baseline and who were
reexamined in the second phase of the study for diabetic status, 35
subjects (17.9%) developed type 2 diabetes mellitus during the 5.8 years
follow-up period. The womenwith type 2 diabetes had lower adiponectin
levels than the healthy postmenopausal women. Multiple regression
analysis showed that, after adjustments were made for age, cardiovas-
cular risk factors, OPG, and hs-CRP levels, higher baseline adiponectin
levels were associated with a lower relative risk (RR) of having type 2
(RR¼ 0.07, confidence interval [CI]: 0.01–0.66, P¼ 0.021).
Higher baseline adiponectin levels functioned as a predictor of a
lower risk of developing type 2 diabetes mellitus among postmenopausal
women during a 5.8 years follow-up study. Therefore, it is suggested that
elevated adiponectin levels may offer protection against the developmentr Asadipooya, MD hdat, MD,
nd Iraj Nabipour, MD
Abbreviations: CI = confidence interval, hs-CRP = high-sensitivity
C-reactive protein, OPG = osteoprotegerin, RR = relative risk.
INTRODUCTION
A dipose-derived cytokines that are collectively called ‘‘adi-pocytokines’’ may be considered to be insulin sensitizers/
insulin-mimetics, and some others may induce insulin resist-
ance.1 Adiponectin is a good adipocytokine that has attracted
great attention due to its antidiabetic, antiinflammatory, and
antiatherogenic properties.2 Adiponectin is negatively corre-
lated with different obesity measures, as well as with insulin
resistance indices.3
Baseline adiponectin levels have been suggested for use
as predictors of type 2 diabetes mellitus by a number of
different studies.4 A systemic review and meta-analysis of 13
prospective studies reported that higher adiponectin levels were
associated with a lower risk of type 2 diabetes in diverse
populations.5
Variations in the adiponectin gene have been reported to be
associated with insulin resistance and type 2 diabetes mellitus.6
Longitudinal data have shown that adiponectin gene poly-
morphisms are associated with the development of hypergly-
cemia.7 Furthermore, genetic variations in the ADIPOQ gene
promoter have been associated with altered serum adiponectin
levels and the progression toward type 2 diabetes.8
Adiponectin suppresses hepatic gluconeogenesis and
stimulates fatty acid oxidation, insulin secretion, and glucose
uptake in skeletal muscles.9 Therefore, this important adipo-
cytokine, which plays a significant role in crosstalk between
adipose tissue and glucose metabolism, should be considered in
glucose homeostasis.
Despite the fact that adiponectin is considered by various
studies to be among the robust biochemical markers for the
prediction of type 2 diabetes mellitus,10 the majority of these
studies have involved Asian populations, or Caucasians from
Europe or North America.11 No study focusing on the
prospective association between adiponectin and type 2 dia-
betes mellitus among general populations from the Middle
East or the Eastern Mediterranean region, who are known to
be at increased risk of diabetes, can be found.12 The preva-
lence of type 2 diabetes mellitus in the total population of the
northern part of the Persian Gulf, in the heart of the Middle
East, is 13%.12 The main aim of this prospective, population-
based study is to investigate the potential link between
baseline adiponectin levels and the future development of
type 2 diabetes mellitus in women. To the best of ourt study is the first to evaluate circulat-
predictor for diabetes among postme-
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METHODS
Community Sampling and Physical Examinations
The study design has been described previously.13 Briefly,
the participants in the present study consisted of an age-stra-
tified random sample of 382 postmenopausal women, who
participated in the extension of the Iranian Multicentral
Osteoporosis Study. The subjects were randomly selected from
13 clusters in the port city of Bushehr (the center of Bushehr
Province, which has the longest border with the Persian Gulf).
The study was approved by the medical ethical committee
of the Bushehr University of Medical Sciences, and written
informed consent was obtained from all subjects.
The baseline examination took place from April 4 to
September 22, 2006. All of the women, who were community
dwelling and ambulatory, were asked to fast and to come to the
survey center between 7:30 and 9:30 AM. On arrival at the survey
site, information regarding the participants’ age, sex, marital
status, and education was recorded. Further questions were
asked about their smoking status, use of postmenopausal hor-
mone replacement therapy, and any drugs taken for angina, as
well as whether they had any history of hypertension, diabetes,
or dyslipidemia. Trained interviewers noted down the infor-
mation using the WHO MONICA questionnaire.14
The participants’ blood pressure was assessed twice, via
the right arm, after a 15-minute rest in sitting position. A
standard mercury sphygmomanometer was used. The women’s
heights and weights were measured using a stadiometer (heavy
outer garments and shoes were removed first) and their body
mass indexes (BMI) were calculated. The participants’ waist
circumferences were measured at the midway level between the
costal margins and the iliac crests, and hip circumferences were
measured at the level of the greater trochanters. A resting
12-lead EKG was also administered.
Laboratory Measurements
Fasting blood samples were taken and promptly centri-
fuged and separated, and analyses were carried out at the
Persian Gulf Health Research Center on the day of blood
collection using a Selectra 2 autoanalyzer (Vital Scientific,
Spankeren, Netherlands). Glucose was assayed by the enzy-
matic (glucose oxidase) colorimetric method using a commer-
cial kit (Pars Azmun, Inc., Tehran, Iran). Serum total cholesterol
and HDL cholesterol were measured using a cholesterol oxidase
phenol aminoantipyrine, and triglycerides were measured using
a glycerol-3 phosphate oxidase phenol aminoantipyrine enzy-
matic method. Serum LDL-cholesterol was calculated using the
Friedewald formula; LDL-cholesterol was not calculated when
the triglyceride concentration was >400mg/dL.
To detect adiponectin in the serum samples, commercially
available ELISA kits (Cat. No. AG-45A-0001EK-KI01;
AdipoGen, Incheon, Korea) were used according to the man-
ufacturer’s instructions. The detection limit of the assay was
100 pg/mL; the intra- and interassay coefficients of variance
were 2.9% to 3.8% and 2.8% to 5.5%, respectively.
Serum osteoprotegerin (OPG) levels were measured using
an ELISA commercial kit (BiomedicaGruppe, Vienna, Austria).
The detection limit of the assay was 0.14 pmol/L. The mean
intra- and interassay coefficients of variation of the OPG assay
were 4% to 10% and 7% to 8%, respectively.
Darabi et alC-reactive protein (CRP) was measured using CRP HS
enzyme-linked immunosorbent assay (ELISA) (DRG
Instruments GmbH, Germany), a highly-sensitive (hs) CRP
2 | www.md-journal.comassay. A concentration of 0.1mg/L for CRP was estimated to
be the lowest concentration detectable via the CRP HS ELISA
assay. According to the interassay coefficient of variation (CV)
<20%, the functional sensitivity of the CRP measurement was
determined to be 0.1mg/L.
Definitions
Using the American Diabetes Association’s criteria, the
existence of diabetes in a patient was defined either by a fasting
plasma glucose level 126mg/dL or by the use of antidiabetic
measures.15
The cut-off points for the serum total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein choles-
terol, and serum triglyceride distributions, which were used to
assign subjects to different risk groups, were derived from the
National Cholesterol Education Program (NCEP) guidelines in
the United States (Adult Treatment Panel [ATP] III).16 A subject
was considered hypertensive if her blood pressure was at least
140/90mm Hg.
Smoking was considered to be present when the subject
smoked cigarettes or used hubble-bubble in a regular daily
fashion. Respondents were classified as active at the recom-
mended level if they reported sufficient physical activities of
moderate intensity (ie,30minutes per day,5 days per week)
or of vigorous intensity (ie, 20minutes per day, 3 days per
week).
Follow-Up Data Collection and Outcome
Classification
The participants were contacted to participate in a 5-year
follow-up study. The follow-up examination occurred at a
median of 5.8 years. At 5-year follow-up study, the baseline
evaluations were repeated and the participants were examined
by an expert endocrinologist in our university research clinic.
New cases of type 2 diabetes mellitus were defined as the
presence of any one of the following: use of prescription
medication for diabetes management or treatment, fasting blood
glucose 126mg/dL. The diagnosis of diabetes was confirmed
by repeat testing in subjects with negative history of diabetes
who had fasting blood glucose 126mg/dL in follow-up study
(11 subjects).15
Statistical Analysis
The distribution of the data was controlled using the
Kolmogorov–Smirnov test. The significance of differences
between the results of any 2 groups was determined via Chi-
square analysis, using 2 2 contingency tables for categorical
variables. A 2-tailed t test was used to compare the mean values
across groups. We found that log transformation of adiponectin,
CrossLaps, sRANKL, and OPG gave a better fit to a Gaussian
distribution. The geometric mean for those biochemical vari-
ables was defined as the arithmetic mean of the log-transformed
dataSD, raised to the power of 10.
Pearson’s correlation analysis was used to study the
relationships between the adiponectin values and the anthropo-
metric and biochemical variables.
Binary logistic regression analysis was used to determine
the association between circulating baseline adiponectin levels
and the future development of type 2 diabetes mellitus. In the
Medicine  Volume 94, Number 33, August 2015full model, baseline adiponectin was the independent variable of
interest, and age, smoking status, physical activity, high blood
pressure, low HDL-cholesterol, high LDL-cholesterol, high
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
diabetes mellitus had significantly lower levels of adiponectin
compared with healthy postmenopausal women. Moreover, the
baseline circulating adiponectin level was a reliable predictor of
TABLE 1. Baseline Characteristics of 382 Postmenopausal Women, Stratified by Serum Adiponectin Below/Equal or Above
Median
AdiponectinMedian Adiponectin>Median P-Value
Age 57.45 7.38 60.33 8.31 0.001
Body mass index (kg/m2) 28.93 4.61 27.87 4.98 0.048
Systolic blood pressure (mm Hg) 125.21 19.95 127 19.64 0.350
Diastolic blood pressure (mm Hg) 81.19 25.86 78.60 10.82 0.242
Fasting blood glucose (mg/dL) 123.87 56.62 103.20 36.54 <0.0001
Total cholesterol (mg/dL) 229.14 44.49 236.51 46.64 0.146
LDL-cholesterol (mg/dL) 150.23 40.48 159.60 40.91 0.039
HDL-cholesterol (mg/dL) 38.26 10.58 43.96 9.91 <0.0001
Triglyceride (mg/dL) 203.14 113.13 164.86 74.46 <0.0001
hs-CRP (mg/L)

2.01 2.95 1.67 2.77 0.116
Osteoprotegerin (pmol/L)

3.68 1.61 3.54 1.52 0.426
Adiponectin (mg/mL)

7.64 1.30 15.45 1.37 <0.0001
Data are given as meanSD unless otherwise indicated.
-cho
TABLE 2. Bivariate Correlation Analysis Between Adiponectin
and Age, Cardiovascular Risk Factors, Osteoprotegerin (OPG),
and High-Sensitivity C-Reactive Protein (hs-CRP) in Postme-
nopausal Women
Log (Adiponectin)
R P-Value
Age 0.187 0.001
Body mass index 0.160 0.004
Systolic blood pressure 0.048 0.392
Diastolic blood pressure 0.043 0.439
Fasting blood glucose 0.209 <0.0001
Total cholesterol 0.029 0.605
LDL-cholesterol 0.057 0.305
HDL-cholesterol 0.276 <0.0001
Triglyceride 0.203 <0.0001
Log (hs-CRP) 0.127 0.022
Log OPG 0.018 0.747
Correlation coefficients and P values were calculated using Pearson
correlation analysis.
Medicine  Volume 94, Number 33, August 2015 Adiponectin and Diabetes in Postmenopausal Womentriglyceride, BMI, hs-CRP, and OPG levels were considered
covariates.
A P-value of less than 0.05 was accepted as significant. All
statistical analyses were performed using PASW Statistics
GradPack 18 (SPSS, Inc., Chicago, IL).
RESULTS
Cross-Sectional Analysis
Table 1 shows the baseline characteristics of the studied
postmenopausal women, stratified into low (below or equal to
the median) and high (above the median) adiponectin groups.
The mean age (meanSD) of the women was 58.6 7.4 years.
Serum adiponectin for the total population (n¼ 382) was at a
median level of 10.81mg/mL.
There were no differences between the 2 groups with regard
to systolic anddiastolic blood pressures, total cholesterol, hs-CRP
levels, and OPG levels. However, the women with low a dipo-
nectin levels (belowmedian)were younger and had higher BMIs,
as well as higher fasting glucose and triglyceride levels. They had
lower HDL-C and LDL-C levels (Table 1).
There was a significant correlation between serum adipo-
nectin levels and age, BMI, fasting blood glucose level, HDL-
cholesterol level, triglyceride level, and hs-CRP level. How-
ever, serum adiponectin levels had no significant correlations
with systolic and diastolic blood pressures, total cholesterol,
LDL-cholesterol, and OPG (Table 2).
Of the studied population, 102 subjects (26.7%) had type 2
diabetes mellitus. The patients with type 2 diabetes were found
to have lower adiponectin levels (9.24 1.46 ng/mL) than the
healthy controls (11.49 1.60 ng/mL) (P< 0.0001).
Prospective Analysis
Of 195 women who did not have diabetes at baseline and
who were reexamined in the second phase of the study for their
diabetic status, 35 subjects (17.9%) had developed type 2
diabetes mellitus over the course of the 5.8 years follow-up
period. The women developed type 2 diabetes mellitus had

Geometric meanSD.LDL-cholesterol¼ low-density lipoprotein
CRP¼ high-sensitivity C-reactive protein.lower adiponectin levels than the healthy controls.
Table 3 shows the unadjusted and adjusted relative risk
(RR) (95% confidence interval [CI]) for serum adiponectin
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.levels and the development of type 2 diabetes mellitus. Age-
adjusted higher baseline adiponectin levels were associated
with a lower RR of having type 2 diabetes mellitus
(Table 3). In logistic regression analysis, this association
remained unchanged after adjusting for further variables,
including cardiovascular risk factors, hs-CRP level, and OPG
level (RR¼ 0.07, CI: 0.01–0.66, P¼ 0.021) (Table 3).
DISCUSSION
In the present study, we found that patients with type 2
lesterol, HDL-cholesterol¼ high-density lipoprotein-cholesterol, hs-LDL-cholesterol¼ low-density lipoprotein-cholesterol, HDL-choles-
terol¼ high-density lipoprotein-cholesterol, hs-CRP¼ high-sensitivity
C-reactive protein, OPG¼ osteoprotegerin.
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TABLE 3. Relative Risk (RR) and Their 95% Confidence Inter-
vals (CI) for Prediction of Type 2 Diabetes (as Dependent
Variable) and Adiponectin Levels (as Independent Variable) in
Different Models
Type 2 Diabetes
RR CI P-Value
Adiponectin (median)
Unadjusted 0.07 0.01–0.58 0.013
Age-adjusted 0.06 0.01–0.48 0.008
Model 1 0.09 0.01–0.75 0.026
Model 2 0.09 0.01–0.79 0.030
Model 3 0.07 0.01–0.66 0.021
Model 1 included adiponectin levels, age and body mass index.
Model 2 included adiponectin levels, age, body mass index, and high-
sensitivity C-reactive protein.
Model 3 included adiponectin levels, age, smoking status, physical
Darabi et alfuture development of type 2 diabetes mellitus in postmeno-
pausal women during a 5.8 years follow-up period. Higher
levels of serum adiponectin were associated significantly with a
lower risk of development of diabetes after adjustments for age,
cardiovascular risk factors, OPG, and hs-CRP were made.
In multiple cross-sectional studies, the inverse relationship
between adiponectin levels, insulin resistance indices, and type
2 diabetes mellitus has been shown.4–17 In addition, the role of
adiponectin in the prediction of type 2 diabetes mellitus has
been clarified in multiple prospective cohort studies from North
America, Europe, and East Asia.11,18,19–23 In accordance with
these studies, we found that adiponectin levels were associated
independently with the development of type 2 diabetes mellitus
during a 5.8 years period. To the best of our knowledge,
the present study provides the first prospective cohort infor-
mation on circulating adiponectin and diabetes among post-
menopausal women. However, Goodarzi et al24 reported that
diabetic postmenopausal women had lower adiponectin levels
compared with age-matched healthy women in a small
case–control study.
Adiposity may be a potential confounding factor in the
relationship between adiponectin and diabetes. We have
demonstrated an inverse association between adiponectin levels
and adiposity measures like BMI and waist-to-hip ratio in
postmenopausal women. In previous studies, different measures
of adiposity, including BMI, waist-to-hip ratio, and body com-
position indices, have been considered using multivariate
adjustments.5 In the present study, adiponectin remained a
significant predictor of type 2 diabetes mellitus after adjust-
ments were made for BMI.
Previous studies have suggested that low-grade systemic
inflammation is involved in the pathogenesis of type 2 diabetes
mellitus,25 which promotes the inclusion of hs-CRP in a type 2
diabetes risk prediction score.26 Adiponectin is an important
antiinflammatory cytokine.27 This adipocytokine has been found
to be negatively correlated with markers of inflammation and
inflammatory responses in vivo and in vitro studies.28–29 In line
activity, high blood pressure, low high-density lipoprotein-cholesterol,
high low-density lipoprotein-cholesterol, high triglyceride, high-sensi-
tivity C-reactive protein, and osteoprotegerin.with these findings, we found that therewas a significant negative
correlation between adiponectin levels and hs-CRP in postme-
nopausalwomen.However, the efficacyof adiponectin levels as a
4 | www.md-journal.compredictor for type 2 diabetes mellitus remained evident after
adjustments were made for hs-CRP levels in the present study.
This finding suggests that the link between adiponectin and the
development of type 2 diabetes mellitus goes beyond to its
association with low-grade systemic inflammation.
The levels of OPG circulation, as an inhibitor of bone
resorption, seem to be elevated in patients with cardiovascular
disorders and diabetes.30We have reported that circulating OPG
levels are associated significantly with diabetes, and that this
association is independent of the cardiovascular risk factors of
postmenopausal women.30 Hence, we used OPG levels as a
potential confounding factor in the multivariate models utilized
in the present study. The results showed that the level of
adiponectin, as a predictor of the development of diabetes,
can be seen as independent from the OPG level.
We acknowledge several limitations. The participants
were not screened for glucose intolerance using oral glucose
tolerance tests. Previous studies confirmed that oral glucose
tolerance test diagnose more people with diabetes mellitus that
HbA1C and fasting blood glucose cut points.31 The power of
our study might be increased to clarify any association between
adiponectin and diabetes by the detection of more new cases of
type 2 diabetes mellitus using oral glucose tolerance test. We
measured total adiponectin and did not differentiate between the
various isoforms of the protein. In some studies, slightly
stronger associations between the risk of diabetes and high-
molecular-weight adiponectin (compared with total adiponec-
tin) have been reported.5 We lost one-third of our cohort during
the 5.8 years follow-up period, which might limit the ability to
generalize the findings. The participants were not screened for
glucose intolerance using oral glucose tolerance tests, which
resulted in a limited ability to detect diabetics via elevated
postchallenge glucose levels. Given that we assessed adiponec-
tin levels using a single measurement, the changes in this
adipocytokine over time could not be demonstrated in the
present study. As the studied adipocytokines are involved in
insulin resistance and the metabolic syndrome, we did not adjust
the regression models for measures of insulin resistance, includ-
ing HOMA-IR. Furthermore, measurements for additional
inflammatory markers, proinflammatory cytokines, and che-
mokines, which are indicators of insulin resistance, merit
consideration to elucidate the complex system that regulates
glucose homeostasis and energy balance.
Our study demonstrates that higher baseline adiponectin
levels are predictors of a lower risk of type 2 diabetes mellitus
among postmenopausal women during a 5.8 years follow-up
period. Elevated adiponectin levels may be a protective factor,
therefore, against the development of type 2 diabetes mellitus
after the menopause.
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